Please login to the form below

Not currently logged in
Email:
Password:

Daiichi-Sankyo gains FDA sNDA for Welchol

The US FDA has approved a supplemental new drug application for Daiichi-Sankyo's cholesterol drug Welchol

The US Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Daiichi-Sankyo's cholesterol drug Welchol.

The sNDA allows Welchol (colesevelam HCl) to be for the reduction of elevated low-density lipoprotein cholesterol (LDL-C), used as an adjunct to diet and exercise, in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH). The drug can be used alone or in addition to a statin once an adequate trial of diet therapy has been tried and failed.

"The FDA approval of Welchol for children with inherited high cholesterol provides another important treatment option for these children, whose elevated LDL cholesterol puts them at increased risk for cardiovascular disease," said Dr Evan A. Stein, director, Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio. "The pivotal trial of Welchol in this paediatric patient population demonstrated that Welchol, as monotherapy or when combined with a statin, significantly reduced LDL-C."

Welchol was approved in 2000, as an adjunct to diet and excerices, as a treatment to lower LDL-C cholesterol in adults with primary hyperlipidemia and to improve glycemic control in adults with type 2 diabetes mellitus. In 2008 it was approved to lower A1C in adults.

12th October 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics